Home » Stocks » SLNO

Soleno Therapeutics, Inc. (SLNO)

Stock Price: $1.11 USD 0.05 (4.72%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.09 -0.02 (-1.80%) May 7, 7:45 PM
Market Cap 88.49M
Revenue (ttm) n/a
Net Income (ttm) -27.74M
Shares Out 79.69M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.11
Previous Close $1.06
Change ($) 0.05
Change (%) 4.72%
Day's Open 1.06
Day's Range 1.06 - 1.11
Day's Volume 952,387
52-Week Range 1.03 - 4.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

3 weeks ago - GlobeNewsWire

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 month ago - Zacks Investment Research

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

2 months ago - GlobeNewsWire

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

2 months ago - Zacks Investment Research

Soleno Therapeutics Inc (NASDAQ: SLNO) drops in premarket trading after the FDA said that it would require an additional controlled clinical trial for DCCR (diazoxide choline) in Prader-Willi Syndrome (...

2 months ago - Benzinga

REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

2 months ago - GlobeNewsWire

Soleno Therapeutics Inc (NASDAQ: SLNO) has signed a collaboration agreement with Vanderbilt University for the discovery and development of KATP channel activators with the potential to treat rare disea...

2 months ago - Benzinga

Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints Recent analysis of Ph...

3 months ago - GlobeNewsWire

Soleno Therapeutics is currently developing Diazoxide Choline Controlled-Release tablets and has a distinctive advantage in how well-documented the safety profile of DCCR's parent molecule, Diazoxide, i...

4 months ago - Seeking Alpha

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

4 months ago - GlobeNewsWire

Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies Soleno intends to submit pl...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

6 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Soleno Therapeutics.

7 months ago - Zacks Investment Research

Updated Results Demonstrate Significant DCCR Exposure Response Relationship

7 months ago - GlobeNewsWire

Soleno (SLNO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

8 months ago - GlobeNewsWire

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.

9 months ago - Zacks Investment Research

If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you covered with t...

Other stocks mentioned: BHF, EYES, JAGX, RMBL
9 months ago - Forbes

Being concerned about the elevated levels of the market is likely to be on many investors’ minds ahead of a slew of corporate earnings coming, not to mention an election season that is only going to get...

Other stocks mentioned: AIRG, BHF, TXMD, VECO
10 months ago - Forbes

As the Nasdaq continues its historic climb, the Dow has erased some of Monday's gains. The coronavirus will continue to make headlines as its cases grow at a consistent rate across 23 states.

Other stocks mentioned: AIM, ALT, BHF, SGBX
10 months ago - Forbes

REDWOOD CITY, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

10 months ago - GlobeNewsWire

REDWOOD CITY, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics ...

10 months ago - GlobeNewsWire

REDWOOD CITY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics f...

10 months ago - GlobeNewsWire

REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics ...

10 months ago - GlobeNewsWire

Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Soleno Therapeutics, Inc. (SLNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia

11 months ago - GlobeNewsWire

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Capnia, Inc. (SLNO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Soleno Therapeutics: A Promising Rare Disease Player For 2020

1 year ago - Seeking Alpha

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

1 year ago - Zacks Investment Research

REDWOOD CITY, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare dis...

1 year ago - GlobeNewsWire

Data Published for First Time in Peer-Reviewed Journal Data Published for First Time in Peer-Reviewed Journal

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...

1 year ago - GlobeNewsWire

Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Capnia.

1 year ago - Zacks Investment Research

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

2 years ago - Zacks Investment Research

Does Capnia, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 years ago - Zacks Investment Research

Shares of thinly traded micro-cap biotech Soleno Therapeutics Inc (NASDAQ: SLNO) were surging Friday on over 700 times their average volume.

2 years ago - Benzinga

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt Un... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 13, 2014
CEO
Anish Bhatnagar
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
SLNO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 530.63% from the latest price.

Price Target
$7.00
(530.63% upside)
Analyst Consensus: Strong Buy